Ramucirumab and Docetaxel in Patients with Metastatic Urothelial Carcinoma Harboring Fibroblast Growth Factor Receptor Alterations: A Case Series and Literature Review
Open Access
- 7 January 2020
- journal article
- case report
- Published by Innovative Healthcare Institute in Journal of Immunotherapy and Precision Oncology
- Vol. 3 (1) , 23-26
Abstract
Metastatic urothelial carcinoma (mUC) has a poor prognosis with a 5-year survival probability of 4.8%. The mainstay of first-line treatment is platinum-based chemotherapy. Second-line therapy involves immune checkpoint inhibitors or a fibroblast growth factor receptor (FGFR) inhibitor, erdafitinib, for patients harboring selected FGFR alterations. Several additional agents are under development for the treatment of mUC. Recent studies demonstrate that ramucirumab and docetaxel have clinical activity in mUC. We report two patients with metastatic upper tract urothelial cancer (mUTUC) with FGFR alterations who were heavily pretreated with FGFR inhibitors that later showed response to ramucirumab and docetaxel. Preclinical studies indicate that FGF and VEGF pathways work synergistically, which could explain the observations in our patients. Our findings may represent another treatment option for patients with mUC and FGFR alterations who have progressed on multiple lines of therapy.Keywords
This publication has 20 references indexed in Scilit:
- Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II TrialJournal of Clinical Oncology, 2016
- Targeting FGFR Signaling in CancerClinical Cancer Research, 2015
- The Fibroblast Growth Factor signaling pathwayWIREs Developmental Biology, 2015
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical PerspectivesCancer Discovery, 2013
- Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasisProceedings of the National Academy of Sciences, 2012
- FGF-dependent regulation of VEGF receptor 2 expression in miceJournal of Clinical Investigation, 2011
- Fibroblast Growth Factor-2-mediated Capillary Morphogenesis of Endothelial Cells Requires Signals via Flt-1/Vascular Endothelial Growth Factor Receptor-1Journal of Biological Chemistry, 2004
- Distinct Role of Fibroblast Growth Factor-2 and Vascular Endothelial Growth Factor on Tumor Growth and AngiogenesisThe American Journal of Pathology, 2003
- Fibroblast Growth Factor-2 (FGF-2) Induces Vascular Endothelial Growth Factor (VEGF) Expression in the Endothelial Cells of Forming Capillaries: An Autocrine Mechanism Contributing to AngiogenesisJournal of Cell Biology, 1998